Previous Page  3 / 22 Next Page
Information
Show Menu
Previous Page 3 / 22 Next Page
Page Background

Page 63

Notes:

Journal of Clinical & Experimental Pathology | ISSN: 2161-0681 | Volume 8

Breast Pathology and Cancer Diagnosis

6

th

World Congress and Expo on

July 25-26, 2018 | Vancouver, Canada

Medicinal Chemistry and Rational Drugs

20

th

International Conference on

&

Study the effects of capsaicin on triple negative breast cancer cells

M Alasmari, Alshaeri, M Bohlke, J Demasi, T Maher

and

A Pino-Figueroa

MCPHS University, USA

T

riple negative breast cancer (TNBC) is one of the most aggressive types of breast cancer. It accounts for 12% of breast

cancer cases. It lacks of estrogen receptor (ER), progesterone receptor (PR), and human epidermal receptor 2 (HER-

2) which limits its treatment options and enhances its ability to metastasize and raises the risk of recurrence. Patients with

TNBC are not responsive to conventional targeted breast cancer therapies. Capsaicin (CAP) is the most abundant and potent

capsaicinoid produced in chili pepper fruits. Capsaicin has been used for its analgesic and anti-inflammatory effects. Moreover,

several studies have shown that capsaicin has anti-carcinogenic properties in various types of human cancers. The aim of this

study is to investigate the effects of capsaicin in human TNBC by using the BT-20 cell line. The results showed that capsaicin

demonstrated concentration and time-dependent inhibitory activity on BT-20 cell viability as determined by MTS assay.

Capsaicin produced cell viability inhibition at concentrations 150 and 250 μM at 24 and 48 h while at 72h it caused inhibition

on cell viability at concentrations of 100, 150 and 250 μM. Capsaicin showed significant 5 fold increase in cytochrome C release

at 250 μM as well as significant 1.6 fold increase in caspase 3/7 activity at 250 μM. Which are markers of apoptotic activation.

In conclusion, capsaicin showed an inhibitory effect on cell growth and enhance apoptosis. These results will provide useful

information regarding the development of a new therapy that can help in treating TNBC.

Biography

Moudi Alasmari is a PhD candidate in pharmacology at Massachusetts College of Pharmacy and Health Sciences University (MCPHS University, Boston, USA).

She completed her MS in pharmacology in 2014 from MCPHS University. She is a Pharm D graduate from King Abdulaziz University (KAU, Jeddah, KSA) in 2009.

She has experience in neuroscience research. She did 3 poster presentations and wrote 1 article under submission in this field. Also, she has been working in

breast cancer research and she did one poster presentation about the anticancer activity of

annona muricata

extract on triple negative breast cancer cells and

isolation/charcterization of active compounds.

alasm1@stu.mcphs.edu

M Alasmari et al., J Clin Exp Pathol 2018, Volume 8

DOI: 10.4172/2161-0681-C3-052